Fluidigm Corp (FLDM)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Fluidigm Corp (FLDM) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011720
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Fluidigm Corp (Fluidigm) formerly known as Mycometrix Corporation, is a biotechnology company which manufactures life-science tools and creates technologies based on microfluidics and mass cytometry. The company’s products systems include biomark HD system, access array system, C1 system, callisto system, EP1 system, polaris system, juno system, and helios. It also provides custom assays such as SNP type assays, maxplar antibodies, delta gene assays and access array assays. Fluidigm offers software, which include fluidigm cytobank analysis, singular analysis toolset, SNP genotyping analysis, real-time PCR analysis, and digital PCR analysis. The company’s C1 system supports mRNA sequencing, DNA sequencing, miRNA analysis and additional applications through the C1 open app IFC. It has operations in France, Canada, Singapore, China, Japan, Australia, the UK and Germany. Fluidigm is headquartered in South San Francisco, California, the US.

Fluidigm Corp (FLDM) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Fluidigm Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Fluidigm Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Fluidigm Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Fluidigm Corp, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Fluidigm Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Fluidigm Corp, Medical Equipment, Deal Details 11
Partnerships 11
Fluidigm Enters into Licensing Agreement with Baylor Genetics Labs 11
Fluidigm Amends Licensing Agreement with Caliper Life Sciences 12
Fluidigm and Ascendas Genomics Enter into Partnership 13
Fluidigm Enters into Distribution Agreement with GenomOncology 14
OpGen Enters into Co-Development Agreement with Fluidigm 15
Fluidigm Enters Into Co-Marketing Agreement With Olink Bioscience For Protein Biomarkers 16
Fluidigm Enters Into Co-Development Agreement With DKMS For High Throughput HLA Typing System 18
Equity Offering 19
Fluidigm Raises USD30 Million in Public Offering of Shares 19
Fluidigm Completes Public Offering Of Common Stock For US$60 Million 20
Fluidigm Completes Underwriters Over-Allotment Of US$86 Million 22
Fluidigm Completes IPO Of Common Stock For US$86.3 Million 24
Debt Offering 26
Fluidigm Completes Public Offering Of Notes Due 2034 For US$201.3 Million 26
Acquisition 28
Fluidigm Completes Acquisition Of DVS Sciences For US$207.5 Million 28
Fluidigm Corp – Key Competitors 30
Fluidigm Corp – Key Employees 31
Fluidigm Corp – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Strategy And Business Planning 33
Aug 04, 2016: Fluidigm Introduces New High-Throughput Targeted NGS Library Preparation System 33
Jun 09, 2016: Fluidigm Announces New Customer Inspiration Center in Canada for Mass Cytometry 34
Financial Announcements 35
Nov 02, 2017: Fluidigm Announces Third Quarter Financial Results and Operational Progress 35
Aug 03, 2017: Fluidigm Announces Second Quarter Financial Results and Operational Progress 37
May 04, 2017: Fluidigm Announces First Quarter Financial Results 39
Feb 08, 2017: Fluidigm Announces Q4 And Full Year 2016 Financial Results 42
Jan 09, 2017: Fluidigm Announces Preliminary Revenue For The Fourth Quarter And Full Year 44
Nov 03, 2016: Fluidigm Announces Third Quarter Financial Results 45
Oct 12, 2016: Fluidigm Announces Preliminary Third Quarter 2016 Revenue 47
Aug 04, 2016: Fluidigm Announces Q2 2016 Financial Results 48
May 05, 2016: Fluidigm Announces First Quarter Financial Results 50
Feb 04, 2016: Fluidigm Announces Q4-Full Year 2015 Financial Results 52
Jan 12, 2016: Fluidigm Announces Preliminary Full Year and Fourth Quarter 2015 Revenue 53
Corporate Communications 54
Mar 27, 2017: Nicolas Barthelemy and Carlos Paya Join Fluidigm Board of Directors 54
Oct 19, 2016: Fluidigm Names S. Christopher Linthwaite as New Chief Executive Officer 55
Aug 04, 2016: Fluidigm Appoints New President and Chief Operating Officer 56
Product News 57
Oct 24, 2017: Fluidigm Introduces Imaging Mass Cytometry System for Highly Multiplexed Protein Detection in Tissues 57
Oct 18, 2017: Fluidigm to Unveil High-Parameter Tissue Imaging System 58
Dec 21, 2016: Fluidigm Introduces A New Medium-Cell High-Throughput Integrated Fluidic Circuit 59
Nov 10, 2016: Fluidigm Introduces High-Parameter Maxpar Mass Cytometry Panels for Immuno-Oncology Research 60
Other Significant Developments 61
Nov 09, 2016: Fluidigm and GenomOncology Partner to Provide Automated Oncology NGS Library Preparation With Molecular Interpretation and Reporting 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Fluidigm Corp, Medical Equipment, Key Facts, 2016 2
Fluidigm Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Fluidigm Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Fluidigm Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Fluidigm Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Fluidigm Corp, Deals By Market, 2011 to YTD 2017 9
Fluidigm Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Fluidigm Enters into Licensing Agreement with Baylor Genetics Labs 11
Fluidigm Amends Licensing Agreement with Caliper Life Sciences 12
Fluidigm and Ascendas Genomics Enter into Partnership 13
Fluidigm Enters into Distribution Agreement with GenomOncology 14
OpGen Enters into Co-Development Agreement with Fluidigm 15
Fluidigm Enters Into Co-Marketing Agreement With Olink Bioscience For Protein Biomarkers 16
Fluidigm Enters Into Co-Development Agreement With DKMS For High Throughput HLA Typing System 18
Fluidigm Raises USD30 Million in Public Offering of Shares 19
Fluidigm Completes Public Offering Of Common Stock For US$60 Million 20
Fluidigm Completes Underwriters Over-Allotment Of US$86 Million 22
Fluidigm Completes IPO Of Common Stock For US$86.3 Million 24
Fluidigm Completes Public Offering Of Notes Due 2034 For US$201.3 Million 26
Fluidigm Completes Acquisition Of DVS Sciences For US$207.5 Million 28
Fluidigm Corp, Key Competitors 30
Fluidigm Corp, Key Employees 31
Fluidigm Corp, Other Locations 32
Fluidigm Corp, Subsidiaries 32

★海外企業調査レポート[Fluidigm Corp (FLDM)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hexion Inc.:企業の戦略・SWOT・財務分析
    SummaryHexion Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings - …
  • KeyCorp:企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "KeyCorp" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric strictly follows a standar …
  • Enerjisa Enerji Uretim AS:発電所・企業SWOT分析
    Enerjisa Enerji Uretim AS - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emp …
  • Sanoma Oyj (formerly SanomaWSOY Oyj):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Sanoma Oyj (formerly SanomaWSOY …
  • Veeco Instruments Inc. (VECO):企業財務及び戦略的SWOT分析
    Summary Veeco Instruments Inc. (Veeco) is a technology company that design, manufacture and market thin film equipments. The company’s products and technologies include MOCVD systems, precision surface processing system, MBE technologies, ion beam systems and sources, physical vapor deposition, gas …
  • Scripps Health-製薬・医療分野:企業M&A・提携分析
    Summary Scripps Health (Scripps) is a non-profit healthcare organization, which provides healthcare services including primary care and urgent and emergency care services; preventive services and wellness screening services in San Diego County in the US. Scripps offers specialized medical care with …
  • Exco Resources, Inc. (XCO):企業の財務及び戦略的SWOT分析
    Summary Exco Resources, Inc. (Exco Resources) is a natural gas and oil company that provides exploration, exploitation, acquisition, development and production of onshore natural gas and oil. The company provides liability management, portfolio repositioning, cost leadership and risk management for …
  • JSC Gazprom Neft:企業のM&A・提携・投資分析
    JSC Gazprom Neft - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's JSC Gazprom Neft Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Invicta Holdings Limited:企業の戦略・SWOT・財務分析
    SummaryInvicta Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Ke …
  • Soft Computing SA (SFT):企業財務及び戦略的SWOT分析
    Summary Soft Computing SA (Soft Computing) is a consulting service provider that specializes in customer relationship management, big data and digital. The company provides marketing services such as council strategic and operational marketing, hosting marketing databases, campaign management, proce …
  • BioFactura Inc-製薬・医療分野:企業M&A・提携分析
    Summary BioFactura Inc (Biofactura) is a biosimilars manufacturer that discovers, develops and markets biodefense drugs and client selected novel drugs. The company offers contract services such as process development, stable cell lines, and manufacturing. Its stable cell lines offers stable mammali …
  • NeoPharm, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' NeoPharm, Inc. Mergers and Acqu …
  • DENSO Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' DENSO Corporation Mergers and A …
  • Becle S.A.B. de C.V. (CUERVO) -Financial and Strategic SWOT Analysis Review
    Becle S.A.B. de C.V. (CUERVO) -Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Sigma-Aldrich Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Sigma-Aldrich Corporation Merge …
  • Nippon Sheet Glass Co Ltd:戦略・SWOT・企業財務分析
    Nippon Sheet Glass Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Nippon Sheet Glass Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Forward Electronics Co., Ltd. (8085):企業概要、財務及び戦略的SWOT分析
    Summary Forward Electronics Co., Ltd. (Forward) is an electronic product manufacturing company. The company designs, manufactures and sells communication and consumer electronic products. It offers optoelectronics, consumer electronics ODM and OEM, audio and video components, and 3C-electronic produ …
  • Clarke, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Clarke, Inc. Mergers and Acquis …
  • Cubic Energy, Inc. (CBNR):企業の財務及び戦略的SWOT分析
    Summary Cubic Energy, Inc. (Cubic) is an upstream energy company that explores, develops and produces activities for crude oil and natural gas. The company concentrates on the integration of earth sciences, engineering, and financial management in oil and gas exploration and development, among other …
  • Volga Gas plc (VGAS):企業の財務及び戦略的SWOT分析
    Summary Volga Gas plc (Volga Gas) is an oil and gas exploration company that acquires, develops and produces oil and natural gas. The company owns assets in Karpenskiy licence area, Vostochny Makarovskoye, Pre-Caspian, and Urozhainoye-2. Volga Gas acquires 3D seismic data for Yuzhny-Ershovskoye. Its …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆